Concord Biotech Balance Sheet Health
Financial Health criteria checks 5/6
Concord Biotech has a total shareholder equity of ₹13.5B and total debt of ₹229.7M, which brings its debt-to-equity ratio to 1.7%. Its total assets and total liabilities are ₹15.5B and ₹2.0B respectively. Concord Biotech's EBIT is ₹3.8B making its interest coverage ratio -426. It has cash and short-term investments of ₹2.3B.
Key information
1.7%
Debt to equity ratio
₹229.67m
Debt
Interest coverage ratio | -426x |
Cash | ₹2.25b |
Equity | ₹13.54b |
Total liabilities | ₹1.97b |
Total assets | ₹15.51b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: CONCORDBIO's short term assets (₹7.6B) exceed its short term liabilities (₹1.7B).
Long Term Liabilities: CONCORDBIO's short term assets (₹7.6B) exceed its long term liabilities (₹292.7M).
Debt to Equity History and Analysis
Debt Level: CONCORDBIO has more cash than its total debt.
Reducing Debt: Insufficient data to determine if CONCORDBIO's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: CONCORDBIO's debt is well covered by operating cash flow (1160.2%).
Interest Coverage: CONCORDBIO earns more interest than it pays, so coverage of interest payments is not a concern.